Preclinical and Clinical Pharmacology of Antisense Oligonucleotides
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 12 (1) , 1-12
- https://doi.org/10.1385/mb:12:1:1
Abstract
Antisense oligonucleotides are short (typically 15–20 bases in length) pieces of synthetically manufactured, chemically modified DNA or RNA. They are designed to interact by Watson-Crick base pairing...Keywords
This publication has 79 references indexed in Scilit:
- Identification of an Oligodeoxynucleotide Sequence Motif That Specifically Inhibits Phosphorylation by Protein Tyrosine KinasesAntisense and Nucleic Acid Drug Development, 1997
- Cancer Chemotherapy in Older AdultsDrugs & Aging, 1997
- Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modificationsNucleic Acids Research, 1996
- Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and manToxicology Letters, 1995
- Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.Proceedings of the National Academy of Sciences, 1994
- Inhibition of kinesin synthesis and rapid anterograde axonal transport in vivo by an antisense oligonucleotideJournal of Biological Chemistry, 1993
- Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer (Oligostick).1992
- Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proceedings of the National Academy of Sciences, 1991
- Control of gene expression by oligonucleotides covalently linked to intercalating agentsGenome, 1989
- Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences, 1978